about
sameAs
Flotillins are involved in the polarization of primitive and mature hematopoietic cellsVesiclepedia: a compendium for extracellular vesicles with continuous community annotationEmerging roles of extracellular vesicles in the nervous systemThe lipid raft microdomain-associated protein reggie-1/flotillin-2 is expressed in human B cells and localized at the plasma membrane and centrosome in PBMCsBACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous systemA paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of β-amyloid production.Asymmetric localization of flotillins/reggies in preassembled platforms confers inherent polarity to hematopoietic cells.Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects.Lipid rafts and membrane dynamics.Alzheimer's disease beta-amyloid peptides are released in association with exosomes.Cellular basis of Alzheimer's diseaseEfficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.Role of genes linked to sporadic Alzheimer's disease risk in the production of β-amyloid peptidesCalcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic lossSuperresolution imaging of amyloid fibrils with binding-activated probesOrder of lipid phases in model and plasma membranesA function for EHD family proteins in unidirectional retrograde dendritic transport of BACE1 and Alzheimer's disease Aβ production.Subcellular targeting strategies for drug design and delivery.The transcellular spread of cytosolic amyloids, prions, and prionoids.Membrane anchored and lipid raft targeted β-secretase inhibitors for Alzheimer's disease therapy.Membrane trafficking pathways in Alzheimer's disease.Lipid-anchored drugs for delivery into subcellular compartments.Retromers in Alzheimer's disease.TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss.Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine.Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway.Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons.Identification of teleost Thy-1 and association with the microdomain/lipid raft reggie proteins in regenerating CNS axons.The launch of Journal of Extracellular Vesicles (JEV), the official journal of the International Society for Extracellular Vesicles - about microvesicles, exosomes, ectosomes and other extracellular vesicles.Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice.miR-186 in Alzheimer's disease: a big hope for a small RNA?Lipid raft redistribution and morphological cell polarization are separable processes providing a basis for hematopoietic stem and progenitor cell migration.Increased Abeta production leads to intracellular accumulation of Abeta in flotillin-1-positive endosomes.Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein.The Alzheimer's Disease γ-Secretase Generates Higher 42:40 Ratios for β-Amyloid Than for p3 Peptides.ObituaryRaft association and lipid droplet targeting of flotillins are independent of caveolinRho Regulates Membrane Transport in the Endocytic Pathway to Control Plasma Membrane Specialization in Oligodendroglial CellsFunctional analyses of cell polarity organization in human hematopoietic stem and progenitor cellsRegulation of dynamic BACE1 trafficking in neurons
P50
Q21142691-CB98FECF-59CA-4BF7-900A-533EE7ABEF63Q21145728-C2957DFB-B15D-437C-B413-48B7A39A3FFDQ27025173-85205738-DBE7-487C-A114-7FF22D60AAD1Q28216973-4F2356C9-3E20-4463-A15F-85FDAA913896Q28480522-6E5A3BCB-871F-4D1A-B5AE-9FF31A31611AQ30577278-D7246BD4-C8D2-463B-AFE6-9FDD55CC4D8CQ30952914-54B6D64B-DBCA-4C34-912F-1423797697A2Q33862796-81302BD1-3E2E-4D22-8F41-63239829F876Q33985713-91A58D32-EC03-4045-9938-BE4E367D570FQ34547007-F2ACF4C9-697A-461A-900C-8662258C8E3BQ34574906-29A09695-96C4-4FB4-8C98-92DC0B788BB6Q34774178-B73E8447-21CE-49B1-A2E1-66D5FAAF4918Q36279869-7BBD1804-0228-4A8E-9035-EF20FB421B85Q36347364-E5727E48-2552-4CB9-BDB1-A13CB28F9F9AQ37025846-6138D468-E20B-4A0A-9DB2-2000E2B38F69Q37377268-DB854B47-BAE3-423F-8AF4-AD07C330BCD3Q37599462-A0B0A347-F2D5-44FD-B01F-092414EDD64CQ37665298-DD60D7F8-B957-4DF4-A8ED-B44BDEC8D1A8Q37671889-F0796456-5CAD-4844-BF70-298DABD27996Q37860837-5769FA68-93DC-4F99-9E7D-6027804D34C1Q37978006-2D112DB6-20A1-42F3-82F5-69E81456AF48Q37990071-9D104B4C-D7E2-4B3A-9B8E-7A525DB64FA6Q37991480-69FCAB65-84DB-4172-9030-A8328ACC1259Q38697913-958F2707-0AE4-4E5F-9158-4A907031284EQ38894992-D1D964C1-6988-4A77-AAB6-B2EFA9787B86Q39796401-8D7A27E6-821E-4236-B228-E01AB9E62109Q40003065-90B5080D-4D3D-4B68-A31C-56E67258053BQ40650658-0FC76CB4-37D2-42A9-8E77-7ED9D8AA3A2BQ42159387-587EDF52-194F-4B3D-82DA-5B9B1D059E67Q45182100-0741544E-4EDC-40C5-B939-752356B67B64Q47626664-1AAE2F71-72E3-46BD-BEE0-1AD669CDF6BBQ47904270-BCDDBCD8-0064-4442-86CC-AC38C5C6AC0CQ48123977-26535160-8DF1-43B7-A6FC-4492A4FDE9C2Q48873213-3D23B37D-11A6-4FC7-82FD-13F346635AAEQ50954994-275482A5-FE94-4B8F-BDC7-8A160B186230Q57084997-A54A7F7E-BF07-4D5C-A626-6AB8B99CBF56Q57375646-9F330702-F4A4-421B-837C-62BAD841B333Q57983952-A3A12DCC-1AEB-4789-92F0-A0B1B7742F8AQ60432482-1758A6BD-F70B-49DF-BA0E-0BF3E9FC73FDQ93598115-958E408D-EFD9-4BB0-8292-3EC1D936AE61
P50
description
medical researcher
@en
onderzoeker
@nl
name
Lawrence Rajendran
@ast
Lawrence Rajendran
@en
Lawrence Rajendran
@es
Lawrence Rajendran
@nl
Lawrence Rajendran
@sl
type
label
Lawrence Rajendran
@ast
Lawrence Rajendran
@en
Lawrence Rajendran
@es
Lawrence Rajendran
@nl
Lawrence Rajendran
@sl
prefLabel
Lawrence Rajendran
@ast
Lawrence Rajendran
@en
Lawrence Rajendran
@es
Lawrence Rajendran
@nl
Lawrence Rajendran
@sl
P106
P166
P21
P31
P496
0000-0002-6390-1821